Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers?

Area of Science:

• Virology
• Immunology
• Oncology

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic, with increasing infections and mortality.
• Clinical worsening of SARS-CoV-2 is associated with comorbidities, highlighting the need for patient stratification and risk identification.
• Cytokines, such as interleukin-6 (IL-6), play a crucial role in the immune response to viral infections and can influence disease severity.

Purpose of the Study:

• To investigate the direct interaction between SARS-CoV-2 and virus-associated cancers.
• To explore the role of interleukin-6 (IL-6) as a mediator in the cross-talk between SARS-CoV-2 infection and cancer.
• To review the potential of targeting IL-6 signaling pathways for therapeutic interventions in SARS-CoV-2 infection.

Main Methods:

• Literature review focusing on the molecular mechanisms linking SARS-CoV-2, comorbidities, and cancer.
• Analysis of existing data on IL-6 production in various viral infections, including SARS-CoV-2.
• Examination of ongoing clinical trials investigating IL-6/IL-6R blockade for SARS-CoV-2 treatment.

Main Results:

• IL-6 production is elevated in SARS-CoV-2 infection and other viral diseases like HPV, HBV, and HIV.
• High systemic IL-6 levels correlate with viral persistence and adverse clinical outcomes in SARS-CoV-2 patients.
• Targeting the IL-6/IL-6R pathway is under investigation, showing potential for managing SARS-CoV-2-associated complications.

Conclusions:

• Interleukin-6 (IL-6) is a critical mediator in the complex interplay between SARS-CoV-2 infection and virus-associated cancers.
• Targeting IL-6 signaling presents a promising therapeutic strategy for patients with SARS-CoV-2, particularly those with comorbidities.
• Further research and clinical trials are essential to validate the efficacy of IL-6 blockade in managing severe SARS-CoV-2 infections and associated conditions.